Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Toni K. Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA; Laurence Albiges, MD, PhD, Gustave Roussy Institute, Paris, France; and Robert A. Figlin, MD, Cedars-Sinai Medical Center, Los Angeles, CA, discuss the potential use of a VEGF tyrosine kinase inhibitor and immune checkpoint inhibitor combination in renal cell carcinoma. They discuss ongoing and completed clinical trials, as well as the future evolution of the treatment landscape.